A Phase 3 interventional study of Brimonidine Tartrate and Vehicle in Hyperemia, sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-23.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hyperemia with a site in United States — 9 open to participants now, 9 under way, 2 of them phase 3. Hyperemia · United States.
Among the 23 studies in Hyperemia with a site in United States, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2013, is one of 6 in phase 3, and was the 3rd registered.
98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.
Browse Hyperemia studies →9 of the 23 studies in Hyperemia with a site in United States are open now. Recruiting first, the newest first:
Alcon Research · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 18+
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, · Sites in United States
Ages 18–65 · Healthy volunteers
Georgia State University · Sites in United States
Ages 20–59
Georgia State University · Sites in United States
Ages 20–65 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Hyperemia studies recruiting now, 17 (61%) set no upper age limit and 7 (25%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 68 across 51 interventional studies indexed under Hyperemia.
Median enrollment 68 across the 19 interventional studies, 40 across the 4 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
Bausch Health Companies Inc. has 3 studies filed under Hyperemia — fewer than ten, so there is no comparison to draw.
6 of the studies in Hyperemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07578363Phase 3Alcon ResearchAn Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults | 2026-11 |
| NCT07531043Phase 3Alcon ResearchEfficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults | 2027-02 |
| NCT07209410Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma | 2026-12-15 |
| NCT06735599Georgia State UniversityWild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure | 2027-01-01 |
| NCT06735651Georgia State UniversityWild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 23 studies in Hyperemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the efficacy and safety of brimonidine tartrate ophthalmic solution 0.025% with its vehicle for the treatment of ocular redness in a population of adult and geriatric participants with ocular redness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
Drug: Brimonidine Tartrate · Drug: Sodium Fluorescein · Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
Drug: Vehicle · Drug: Sodium Fluorescein · Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Ophthalmic solution to be applied as directed.
Ophthalmic solution to be applied as directed.
For use as needed during the study for evaluating corneal damage.
For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
Ocular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia Scale
Ocular redness using the Ora Calibra Ocular Hyperemia Scale was scored by the Investigator using the following scale (allowing half unit increments): 0=None; 1.0=Mild-Slightly dilated blood vessels, color of vessels is typically pink, can be quadrantal; 2.0=Moderate-More apparent dilation of blood vessels, vessel color is more intense (redder), involves the majority of the vessel bed; 3.0=Severe-Numerous and obvious dilated blood vessels, in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4.0=Extremely Severe-Large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed. A lower score is indicative of less redness.
Time frame: 0 (predose), 5, 15, 30, 60, 90, 120, 180, and 240 minutes postdose on Day 1
Ocular Redness as Measured by the Participant
Ocular redness was scored daily pre-dose and post-dose on Days 1 to 29 and scored daily on Days 30 to 36 by the participant using a 0 to 4 unit scale (not allowing half unit increments). A lower score was indicative of less redness. The LOCF method used for this Secondary Outcome Measure was for imputing missing daily post-dose mean scores for entire days. If ≥1 score was provided for a day, imputation was not done. Imputation was done within the dosing period and separately within the follow-up period. The average (mean) daily pre-dose and post-dose scores for the dosing period Day 1 to Day 15 and dosing period Day 15 to Day 29, and the average (mean) daily score for the follow-up period Day 29 to Day 36 are reported.
Time frame: Day 1 to Day 15; Day 15 to Day 29; Day 29 to Day 36
Change From Predose Ocular Redness Score as Measured by the Investigator Using the Ora Calibra Ocular Hyperemia Scale
Ocular redness using the Ora Calibra Ocular Hyperemia Scale was scored by the Investigator using the following scale (allowing half unit increments): 0=None; 1.0=Mild-Slightly dilated blood vessels, color of vessels is typically pink, can be quadrantal; 2.0=Moderate-More apparent dilation of blood vessels, vessel color is more intense (redder), involves the majority of the vessel bed; 3.0=Severe-Numerous and obvious dilated blood vessels, in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4.0=Extremely Severe-Large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed. A lower score is indicative of less redness.
Time frame: 0 (predose), 1, 360, and 480 minutes (min) postdose on Day 1 and 0 (predose), 1, and 5 min postdose on Days 15 and 29
| Milestone | Brimonidine Tartrate | Brimonidine Tartrate Vehicle |
|---|---|---|
| Started | 40 | 20 |
| Received at least 1 dose of study drug | 40 | 20 |
| Completed | 36 | 19 |
| Not completed | 4 | 1 |
| Withdrew: Failure to follow study procedures | 0 | 1 |
| Withdrew: Administrative reasons | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
Ocular redness using the Ora Calibra Ocular Hyperemia Scale was scored by the Investigator using the following scale (allowing half unit increments): 0=None; 1.0=Mild-Slightly dilated blood vessels, color of vessels is typically pink, can be quadrantal; 2.0=Moderate-More apparent dilation of blood vessels, vessel color is more intense (redder), involves the majority of the vessel bed; 3.0=Severe-Numerous and obvious dilated blood vessels, in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4.0=Extremely Severe-Large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed. A lower score is indicative of less redness.
| units on a scale | Brimonidine Tartrate | Brimonidine Tartrate Vehicle |
|---|---|---|
| Predose | 1.82 ± 0.412 | 1.71 ± 0.365 |
| 5 minutes Postdose | 0.58 ± 0.497 | 1.40 ± 0.666 |
| 15 minutes Postdose | 0.58 ± 0.497 | 1.35 ± 0.651 |
| 30 minutes Postdose | 0.59 ± 0.511 | 1.40 ± 0.641 |
| 60 minutes Postdose | 0.61 ± 0.509 | 1.40 ± 0.646 |
| 90 minutes Postdose | 0.60 ± 0.476 | 1.45 ± 0.672 |
| 120 minutes Postdose | 0.63 ± 0.470 | 1.53 ± 0.612 |
| 180 minutes Postdose | 0.73 ± 0.449 | 1.54 ± 0.586 |
| 240 minutes Postdose | 0.82 ± 0.474 | 1.54 ± 0.575 |
Ocular redness was scored daily pre-dose and post-dose on Days 1 to 29 and scored daily on Days 30 to 36 by the participant using a 0 to 4 unit scale (not allowing half unit increments). A lower score was indicative of less redness. The LOCF method used for this Secondary Outcome Measure was for imputing missing daily post-dose mean scores for entire days. If ≥1 score was provided for a day, imputation was not done. Imputation was done within the dosing period and separately within the follow-up period. The average (mean) daily pre-dose and post-dose scores for the dosing period Day 1 to Day 15 and dosing period Day 15 to Day 29, and the average (mean) daily score for the follow-up period Day 29 to Day 36 are reported.
| units on a scale | Brimonidine Tartrate | Brimonidine Tartrate Vehicle |
|---|---|---|
| Daily Predose Score of Day 1 to Day 15 | 1.52 ± 0.857 | 1.83 ± 0.975 |
| Daily Postdose Score of Day 1 to Day 15 | 0.85 ± 0.860 | 1.85 ± 0.843 |
| Daily Predose Score of Day 15 to Day 29 | 1.45 ± 0.811 | 1.59 ± 1.012 |
| Daily Postdose Score of Day 15 to Day 29 | 0.80 ± 0.810 | 1.63 ± 0.887 |
| Daily Score of Day 29 to Day 36 | 1.69 ± 0.885 | 1.69 ± 0.897 |
Ocular redness using the Ora Calibra Ocular Hyperemia Scale was scored by the Investigator using the following scale (allowing half unit increments): 0=None; 1.0=Mild-Slightly dilated blood vessels, color of vessels is typically pink, can be quadrantal; 2.0=Moderate-More apparent dilation of blood vessels, vessel color is more intense (redder), involves the majority of the vessel bed; 3.0=Severe-Numerous and obvious dilated blood vessels, in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4.0=Extremely Severe-Large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed. A lower score is indicative of less redness.
| units on a scale | Brimonidine Tartrate | Brimonidine Tartrate Vehicle |
|---|---|---|
| Predose on Day 1 | 1.82 ± 0.412 | 1.71 ± 0.365 |
| Change from Predose at 1 min Postdose on Day 1 | -1.06 ± 0.625 | -0.23 ± 0.486 |
| Change from Predose at 360 min Postdose on Day 1 | -0.78 ± 0.517 | -0.10 ± 0.440 |
| Change from Predose at 480 min Postdose on Day 1 | -0.63 ± 0.570 | -0.13 ± 0.459 |
| Predose on Day 15 | 1.57 ± 0.645 | 1.24 ± 0.349 |
| Change from Predose at 1 min Postdose on Day 15 | -0.78 ± 0.496 | -0.16 ± 0.279 |
| Change from Predose at 5 min Postdose on Day 15 | -1.03 ± 0.569 | -0.25 ± 0.354 |
| Predose on Day 29 | 1.64 ± 0.461 | 1.36 ± 0.304 |
| Change from Predose at 1 min Postdose on Day 29 | -0.88 ± 0.469 | -0.24 ± 0.306 |
| Change from Predose at 5 min Postdose on Day 29 | -1.21 ± 0.416 | -0.37 ± 0.347 |
Collected over Baseline up to Day 36. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brimonidine Tartrate | — | 0/40 (0%) | 10/40 (25%) |
| Brimonidine Tartrate Vehicle | — | 0/20 (0%) | 1/20 (5%) |
| Event | Brimonidine Tartrate | Brimonidine Tartrate Vehicle |
|---|---|---|
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/40 | 1/20 |
| BronchitisInfections and infestations | 1/40 | 0/20 |
| Foreign body sensation in eyesEye disorders | 1/40 | 0/20 |
| Lacrimation increasedEye disorders | 1/40 | 0/20 |
| Abdominal discomfortGastrointestinal disorders | 1/40 | 0/20 |
| Eye pruritusEye disorders | 1/40 | 0/20 |
| Temporomandibular joint syndromeMusculoskeletal and connective tissue disorders | 1/40 | 0/20 |
| PainGeneral disorders | 1/40 | 0/20 |
| Muscle strainInjury, poisoning and procedural complications | 1/40 | 0/20 |
| NasopharyngitisInfections and infestations | 1/40 | 0/20 |
All randomized participants who received at least 1 dose of study drug (Safety Population).
| Age, Continuous(years) | Brimonidine Tartrate | Brimonidine Tartrate Vehicle | Total |
|---|---|---|---|
| Mean | 47.6 ± 15.37 | 47.4 ± 15.36 | 47.5 ± 15.24 |
| Sex: Female, Male(Participants) | Brimonidine Tartrate | Brimonidine Tartrate Vehicle | Total |
|---|---|---|---|
| Female | 22 | 16 | 38 |
| Male | 18 | 4 | 22 |
Ran from Nov 2013 to primary completion in Dec 2013, 1 month.
Results were first posted in Oct 2019, 5 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine